By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panelists agree that MGK and IWM serve different roles and neither is clearly better; the choice depends on macro view and time horizon. Key risks include MGK's high tech concentration and IWM's high exposure to unprofitable firms. Key opportunity is potential M&A-driven growth in IWM during rate cut cycles.
Risk: MGK's high tech concentration
Opportunity: Potential M&A-driven growth in IWM during rate cut cycles
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
The iShares Russell 2000 ETF tracks small-cap stocks while the Vanguard Mega Cap Growth ETF focuses on the largest growth companies in the U.S. market.
The Vanguard Mega Cap Growth ETF carries a lower expense ratio of 0.05% compared to the 0.19% charged by iShares Russell 2000 ETF.
The Vanguard Mega Cap Growth ETF is heavily concentrated in technology while the iShares Russell 2000 ETF provides broader exposure across healthcare, industrials, and financial services.
Comparing the Vanguard Mega Cap Growth ETF (NYSEMKT:MGK) and iShares Russell 2000 ETF (NYSEMKT:IWM) involves weighing the high-octane growth of tech giants against the diverse, more volatile landscape of small-cap companies.
Investors often choose between these funds to adjust their market-cap exposure. The Vanguard fund captures the top tier of growth leaders, while the iShares fund tracks the broader small-cap market. This comparison looks at how their costs, holdings, and risk profiles differ for long-term holders.
| Metric | MGK | IWM | |---|---|---| | Issuer | Vanguard | iShares | | Expense ratio | 0.05% | 0.19% | | 1-yr return (as of May 6, 2026) | 36.40% | 47.30% | | Dividend yield | 0.34% | 0.90% | | Beta | 1.23 | 1.30 | | AUM | $32.03 billion | $76.88 billion |
Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
The Vanguard fund is more affordable, costing just $0.50 annually for every $1,000 invested compared to $1.90 for its counterpart. While both pay dividends, the Vanguard fund currently offers a lower payout with a trailing-12-month yield of 0.34% compared to 0.90% for the iShares fund.
| Metric | MGK | IWM | |---|---|---| | Max drawdown (5 yr) | (36.00%) | (31.90%) | | Growth of $1,000 over 5 years (total return) | $2,029 | $1,353 |
The iShares Russell 2000 ETF provides exposure to 1,924 small-cap stocks. Its portfolio is led by healthcare at 18%, industrials at 17%, and financial services at 16%. Its largest positions include Bloom Energy (NYSE:BE) at 1.93%, Credo Technology (NASDAQ:CRDO) at 0.94%, and Sterling Infrastructure (NASDAQ:STRL) at 0.72%. This fund was launched in 2000, features no significant quirks, and has a trailing-12-month dividend of $2.54 per share.
In contrast, the Vanguard Mega Cap Growth ETF is more concentrated, holding 59 stocks. It tilts heavily toward technology at 68%, followed by consumer discretionay at 16% and industrials at 6%. Top holdings include NVIDIA (NASDAQ:NVDA) at 13.73%, Apple (NASDAQ:AAPL) at 12.58%, and Microsoft (NASDAQ:MSFT) at 9.00%. Launched in 2007, it has no major quirks and a trailing-12-month dividend of $1.18 per share.
For more guidance on ETF investing, check out the full guide at this link.
The iShares Russell 2000 ETF (IWM) and Vanguard Mega Cap Growth ETF (MGK) offer different ways for investors to pursue growth-oriented stocks. The choice between these two comes down to which strategy best meets your investing goals.
MGK’s large-cap focus gives you access to the biggest names in the tech sector for a very low expense ratio. Thanks to artificial intelligence, technology stocks have soared, helping MGK deliver strong recent growth. However, its small set of 59 stocks provides little diversification, so whenever the tech industry experiences a downturn, the fund’s performance will suffer, as demonstrated by its higher max drawdown. MGK is for investors who want to concentrate on companies with large market caps and are comfortable with the risks.
IWM takes the opposite approach to growth, targeting a wide range of small companies, which offer the potential for rapid business expansion. The ETF’s broad holdings protect it from a decline in any given sector or stocks, and its larger AUM delivers good liquidity. The downside is its much higher expense ratio, and small-cap stocks inherently possess greater volatility than the stability afforded by large caps. IWM is good for investors who want to add small-cap exposure to round out their portfolios.
Before you buy stock in iShares Trust - iShares Russell 2000 ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and iShares Trust - iShares Russell 2000 ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $475,926! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,296,608!
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 8, 2026. *
Robert Izquierdo has positions in Apple, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Apple, Bloom Energy, Microsoft, Nvidia, and Sterling Infrastructure. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"MGK acts as a momentum-driven tech proxy while IWM functions as a high-beta cyclical play, making them tools for tactical allocation rather than long-term core holdings for most investors."
Comparing MGK and IWM is a false equivalence; they serve entirely different roles in portfolio construction. MGK is essentially a proxy for the 'Magnificent Seven' and the AI-driven momentum trade. Its 68% tech concentration makes it a beta-play on high-multiple growth, which is vulnerable to any compression in valuation multiples if interest rates stay 'higher for longer.' Conversely, IWM is a cyclical bet on domestic economic health. The article misses the critical impact of the debt maturity wall facing small-cap companies; with floating-rate debt exposure, IWM’s constituents face significantly higher refinancing risks than the cash-rich balance sheets of MGK’s mega-caps. I am neutral on both, as the macro environment favors neither extreme.
If the Federal Reserve initiates a sustained cutting cycle, IWM could experience a massive 'catch-up' rally as small-cap financing costs collapse, potentially outperforming the already expensive, high-multiple mega-caps in MGK.
"MGK outperforms as the true growth ETF with 50% better 5-year returns and 3x lower costs, despite the article's apples-to-oranges matchup with broad small-cap IWM."
This comparison is flawed at its core: MGK is a concentrated mega-cap growth ETF (68% tech, NVDA/AAPL/MSFT top holdings), while IWM tracks the broad Russell 2000 small-cap index, which blends growth and value (18% healthcare, 17% industrials, 16% financials)—not a pure growth play as the title implies. MGK's 0.05% expense ratio crushes IWM's 0.19%, and its 5-year total return ($1,000 to $2,029 vs $1,353) proves mega-cap growth's edge, despite a slightly higher max drawdown (-36% vs -31.9%). IWM's 47% 1-year win is likely a cyclical rate-cut rotation; for structural growth, MGK dominates long-term.
If Fed rate cuts accelerate into 2026, IWM's small caps—trading at historically low valuations—could sustain outperformance with better diversification and lower drawdowns, exposing MGK's tech bubble risk (13% NVDA weight).
"The article conflates 'lower fees' with 'better value' while ignoring that MGK's 36% drawdown and 68% tech concentration make it a sector bet, not a diversified growth play."
This article frames a false choice. MGK and IWM aren't competing growth vehicles—they're orthogonal bets. MGK's 36% 1-yr return masks a brutal 36% max drawdown; it's a concentrated tech levered play, not diversified growth. IWM's 47% return and lower drawdown suggest small-caps have outperformed mega-cap tech recently, yet the article treats MGK as the 'safer' option because of lower fees. The real issue: both are cyclical. MGK's 68% tech weighting means it's hostage to AI sentiment and rate expectations. IWM's 18% healthcare + 17% industrials offer genuine diversification, but at 0.19% fees that compound into real drag over 30 years. Neither is obviously better; the choice depends entirely on your macro view and time horizon.
If the AI supercycle persists and mega-cap tech sustains 15%+ EPS growth, MGK's 1.23 beta and concentrated exposure to NVDA/MSFT/AAPL could deliver 20%+ annualized returns that dwarf IWM's small-cap volatility drag—making the fee comparison irrelevant.
"MGK offers the low-cost mega-cap bet, but its concentration risk and rate/regulatory sensitivities mean a balanced approach with IWM may better weather regime shifts."
MGK’s allure is clear: 0.05% expense and exposure to the AI-driven mega-cap growth rally (NVDA 13.73%, AAPL 12.58%, MSFT 9.00%). Yet the article glosses over real risks: MGK is a 59-stock, tech-heavy sleeve with a 68% tech tilt, making it highly concentrated and vulnerable to a reversal in AI momentum or regulatory headwinds; the 5-year max drawdown was worse than IWM’s, and a large portion of returns hinges on a few names. IWM offers broad small-cap diversification (1,924 holdings) and a higher dividend cushion, but at a higher cost. The decision hinges on regime bets (growth vs. dispersion, rate paths, policy).
MGK could outperform if AI-driven growth remains durable and mega-cap leaders extend their dominance; diversification of IWM might underperform in a sustained upcycle. The article’s favorable MGK framing risks cherry-picking metrics and ignores concentration and regulatory risks.
"IWM's diversification is misleading because a significant portion of its constituents are structurally unprofitable, making them a quality trap rather than a growth play."
Grok, you argue IWM's 47% 1-year return is a 'cyclical rotation' while dismissing MGK's concentration as 'structural growth.' This is a dangerous recency bias. IWM’s index composition is heavily skewed toward unprofitable firms—roughly 40% of the Russell 2000 constituents have negative earnings. That isn't just 'diversification'; it’s a structural quality trap. If the Fed cuts rates, you aren't buying growth; you're buying a massive, leveraged bet on zombie balance sheets that may never reach profitability.
"IWM's profitable half offers valuation edge and M&A upside ignored by MGK bulls."
Gemini nails IWM's 40% unprofitable names as a quality trap, but overlooks the profitable cohort trading at 13x forward P/E (vs. MGK's 35x+) with superior FCF yields. Unmentioned second-order effect: Fed cuts ignite small-cap M&A (Russell 2000 led deals by 25% historically in cut cycles), potentially driving 15-20% catch-up EPS growth that compresses MGK's premium.
"IWM's valuation discount reflects genuine quality risk, not just cyclical repricing."
Grok's M&A thesis is speculative—Russell 2000 M&A upticks in cut cycles don't automatically compress MGK's premium if acquirers are financial buyers, not strategic consolidators seeking synergies. More critically: IWM's 13x forward P/E assumes those profitable names sustain earnings; 40% unprofitable constituents create a denominator problem if recession hits. Gemini's zombie balance sheet warning deserves weight here—cheap multiples often signal distress, not opportunity.
"The M&A catch-up thesis for small caps is unlikely to reliably lift EPS; financing, profitability, and regulatory risks overshadow near-term gains."
Grok's 'cut-cycle M&A catch-up' thesis feels overstretched. It assumes easy debt, optimistic profitability, and aggressive acquirers will push small caps higher; in practice, financing costs can stay elevated, deal-flow can stall, and dilution or integration costs offset near-term EPS gains. If the 'zombie' risk persists, many Russell 2000 names may never deliver sustained improvement. In that regime, MGK's AI-driven beta could still outpace on a pure momentum or rate-cut rotation, not on M&A bet.
The panelists agree that MGK and IWM serve different roles and neither is clearly better; the choice depends on macro view and time horizon. Key risks include MGK's high tech concentration and IWM's high exposure to unprofitable firms. Key opportunity is potential M&A-driven growth in IWM during rate cut cycles.
Potential M&A-driven growth in IWM during rate cut cycles
MGK's high tech concentration